drugset
drugset / Trial / NCT02718443

VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma

NCT02718443 ↗

Phase 1 Completed 14 enrolled Vaximm GmbH
NaSingle-groupOpen-labelTreatment

Summary

VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01

Timeline

Start
2016-05
Primary completion
2017-08
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Subject VXM01 Vaccine 1e+06 unknown Oral
Subject VXM01 Vaccine 1e+07 unknown Oral

Indications

glioblastoma